Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Chinese CREG 5.44 bouncing some off 5.19 LOD on it's first day of trading on NASDAQ...rallied into the close Friday...maybe it will do the same today possibly?! tuna
CREG 5.44 -.29 rallied late Friday...like to see the same today for it's first day of trading on NASDAQ coming off 5.19 LOD so far...tuna
Chinese LPIH 2.28 +.23 another new HOD on good volume with presentation tomorrow morning at the NASDAQ site in NYC...tuna
Also added SOKF 4.11 +.11 as this Chinese profitable company presents in NYC during the 23rd/24th (Tues/Wed) RedChip presentations...here's recent headlines:
•Economic Commentators Charles Payne and Stephen Moore to Present at RedChip's 2010 New York Equities Growth Conference
GlobeNewswire(Mon 11:46am)
•SOKO Fitness & Spa Group to Present at Upcoming Investor Conferences
PR Newswire(Thu, Mar 4)
•SOKO FITNESS & SPA GROUP, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
EDGAR Online(Wed, Feb 24)
•SOKO Fitness & Spa Group Completes Construction of Yoga Wave Harbin
PR Newswire(Tue, Feb 23)
•SOKO FITNESS & SPA GROUP, INC. Financials
EDGAR Online Financials(Wed, Feb 10)
•SOKO Fitness & Spa Group Broadens Geographic Expansion Strategy
PR Newswire(Wed, Feb 10)
•SOKO FITNESS & SPA GROUP, INC. Files SEC form 10-Q/A, Quarterly Report
EDGAR Online(Wed, Feb 3)
•SOKO FITNESS & SPA GROUP, INC. Files SEC form 8-K/A, Changes in Registrant's Certifying Accountant, Financial Stateme
EDGAR Online(Fri, Jan 15)
•SOKO Fitness Reports Second Quarter Fiscal 2010 Results
PR Newswire(Thu, Jan 14)
tuna
Thanks for the BLGW chart WANG...like the steady gains recently...not huge gains that are unsustainable...tuna
Chinese SOKF 4.10 +.10 on largest volume in 6 mos...presents in 23rd-24th NYC RedChip presentations:
•Economic Commentators Charles Payne and Stephen Moore to Present at RedChip's 2010 New York Equities Growth Conference
GlobeNewswire(Mon 11:46am)
•SOKO Fitness & Spa Group to Present at Upcoming Investor Conferences
PR Newswire(Thu, Mar 4)
•SOKO FITNESS & SPA GROUP, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
EDGAR Online(Wed, Feb 24)
•SOKO Fitness & Spa Group Completes Construction of Yoga Wave Harbin
PR Newswire(Tue, Feb 23)
•SOKO FITNESS & SPA GROUP, INC. Financials
EDGAR Online Financials(Wed, Feb 10)
•SOKO Fitness & Spa Group Broadens Geographic Expansion Strategy
PR Newswire(Wed, Feb 10)
•SOKO FITNESS & SPA GROUP, INC. Files SEC form 10-Q/A, Quarterly Report
EDGAR Online(Wed, Feb 3)
•SOKO FITNESS & SPA GROUP, INC. Files SEC form 8-K/A, Changes in Registrant's Certifying Accountant, Financial Stateme
EDGAR Online(Fri, Jan 15)
•SOKO Fitness Reports Second Quarter Fiscal 2010 Results
PR Newswire(Thu, Jan 14)
And Chinese energy LPIH 2.26 +.21 new HOD!!
Yeah I guess WANG...still like CREG though with it's strong earnings growth and I'll stay with it...tuna
YW! I'm also in BLGW .99 LPIH 2.25 EBIG .15 APT 3.36 CREG 5.30(it's first day of trading on Nasdaq...Chinese co. with strong rev/earnings growth) SCLN 3.81 and NEWN 7.15 too WANG! In for more than day trades on all of these....tuna
Thanks WANG...doing fine and still mostly in Chinese stocks that are profitable and with low PE's...CREG is another but it's down hard today on it's first day of trading on NASDAQ! I'll hang with it though due to it's strong earnings and revenue growth...hope all has been well for you during my absence too!! Nice to be back again! tuna
Or some might even say stupid but I like what I see in SNBP BRIG...nice when you get into a company this has just gone from a loss to a profit on this latest Q report vs the same Q last year. tuna
Added Chinese SNBP .26 after seeing last earnings report showing strong revenue growth and a move to profitability for the Q vs same Q '08. Also, this PR is huge for them also imho:
China's Basic Medical Insurance to Cover Sinobiopharma's Flagship Product
Basic Insurance to Cover 90 Percent of China's Urban Population of 600 Million by the End of 2010
Press Release Source: Sinobiopharma, Inc. On Monday February 1, 2010, 8:30 am EST
NANTONG, China, Feb. 1 /PRNewswire-Asia/ -- Sinobiopharma, Inc. ("Sinobiopharma" or, the "Company") (OTC Bulletin Board: SNBP) is pleased to announce that the Chinese government has approved the Company's flagship product, KuTai (Cisatracurium Besylate), for coverage under National Basic Medical Insurance, Employment Injury Insurance and Maternity Insurance (2009 Edition).
KuTai (Cisatracurium Besylate), on the market since 2006, had not been covered by any medical insurance before the Chinese government granted approval for its inclusion on the list of insured drugs on November 27, 2009. Before coverage was approved, patients who chose KuTai, a lasted generation skeletal muscle relaxant used for surgery, did so at their own expense. National Basic Medical Insurance will now provide for patients to be reimbursed for any use of KuTai. Under China's healthcare reform plan, more than 90 percent of its urban population of 600 million will be covered by National Basic Medical Insurance by the end of 2010.
Typically, the Chinese government observes the performance of new generation drugs in the market for several years to ensure their safety and efficacy profile is well established before considering them for inclusion on the list of insured pharmaceuticals. Following Sinobiopharma's launch of this latest generation of muscle relaxant in China in 2006, KuTai has became one of the market growth leaders and is now used in more than 1,000 hospitals located in almost every province.
"We are very pleased that KuTai has finally been approved for insurance coverage," said Dr. Lequn Lee Huang, Sinobiopharma CEO. "All of KuTai's competitor drugs, earlier generation muscle relaxants, were covered by insurance. But even with this reimbursement disadvantage, KuTai still managed to gain significant market share because of its greater efficacy and superior safety profile. KuTai's inclusion on the list of insured drugs eliminates this reimbursement disadvantage. We expect the provision of insurance coverage will drive a significant increase in KuTai's sales volume and further gains in market share."
tuna
Chinese SNBP .265 +.01 new HOD!
LPIH 2.25 +.20 HOD presenting at NASDAQ site in NYC at 10:30 EDT tomorrow!! tuna
And BLGW .99 +.025 ask getting hit w/nearly 1/2mil. shares traded already today...like the chances of a buck+ very soon on this advertising company which ranks tops in it's field in Europe, 3rd in the US and announced recently they're moving into Asia also!! tuna
This is huge news for SNBP .26 also:
China's Basic Medical Insurance to Cover Sinobiopharma's Flagship Product
Basic Insurance to Cover 90 Percent of China's Urban Population of 600 Million by the End of 2010
Buzz up! 0 Print..Companies:SINOBIOPHARMA, INC.Related Quotes
Symbol Price Change
SNBP.OB 0.2599 +0.0049
{"s" : "snbp.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""} Press Release Source: Sinobiopharma, Inc. On Monday February 1, 2010, 8:30 am EST
NANTONG, China, Feb. 1 /PRNewswire-Asia/ -- Sinobiopharma, Inc. ("Sinobiopharma" or, the "Company") (OTC Bulletin Board: SNBP) is pleased to announce that the Chinese government has approved the Company's flagship product, KuTai (Cisatracurium Besylate), for coverage under National Basic Medical Insurance, Employment Injury Insurance and Maternity Insurance (2009 Edition).
KuTai (Cisatracurium Besylate), on the market since 2006, had not been covered by any medical insurance before the Chinese government granted approval for its inclusion on the list of insured drugs on November 27, 2009. Before coverage was approved, patients who chose KuTai, a lasted generation skeletal muscle relaxant used for surgery, did so at their own expense. National Basic Medical Insurance will now provide for patients to be reimbursed for any use of KuTai. Under China's healthcare reform plan, more than 90 percent of its urban population of 600 million will be covered by National Basic Medical Insurance by the end of 2010.
Typically, the Chinese government observes the performance of new generation drugs in the market for several years to ensure their safety and efficacy profile is well established before considering them for inclusion on the list of insured pharmaceuticals. Following Sinobiopharma's launch of this latest generation of muscle relaxant in China in 2006, KuTai has became one of the market growth leaders and is now used in more than 1,000 hospitals located in almost every province.
"We are very pleased that KuTai has finally been approved for insurance coverage," said Dr. Lequn Lee Huang, Sinobiopharma CEO. "All of KuTai's competitor drugs, earlier generation muscle relaxants, were covered by insurance. But even with this reimbursement disadvantage, KuTai still managed to gain significant market share because of its greater efficacy and superior safety profile. KuTai's inclusion on the list of insured drugs eliminates this reimbursement disadvantage. We expect the provision of insurance coverage will drive a significant increase in KuTai's sales volume and further gains in market share.
tuna
Thanks WANG!! It's a hold for probably at least through the next earnings...strong momentum in the company going forward it appears to me...tuna
Another Chinese stock I like a lot is SNBP .26 here that I added last week and put it in the wife's account today...look at their impressive earnings report for the latest Q:
Announces Second Quarter 2010 Financial Results
Revenue Increases to Approximately $2.1 Million; Net Income Increases to Approximately $1.1 Million
Press Release Source: Sinobiopharma, Inc. On Tuesday January 19, 2010, 8:30 am EST
NANTONG CITY, China, Jan. 19 /PRNewswire-Asia-FirstCall/ -- Sinobiopharma, Inc. (OTC Bulletin Board: SNBP, "Sinobiopharma" or the "Company"), a fully integrated and highly innovative biopharmaceutical company engaged in the research and development, manufacture and marketing of pharmaceutical products in China, today announced financial results for the second quarter ended November 30, 2009.
Second Quarter 2010 Highlights -- Total revenue increased by 120% year over year to approximately $2.1 million. -- Gross margin increased 182% year over year to approximately $1.7 million, or 80% of sales. -- Net income increased $2.1 million from a net loss of approximately $1.0 million in the second quarter of 2009 to net income of approximately $1.1 million in the second quarter of 2010. -- The Company scaled up of production and marketing to launch Sinobiopharma's new drug YiTai (perindopril).
"We achieved excellent revenue and net income growth in the second quarter," said Dr. Lequn Huang, Sinobiopharma's Chairman and CEO stated. "The strong growth is largely due to our increased marketing efforts and strong demand for our main product KuTai (cisatracurium besylate). KuTai is replacing older-generation muscle relaxants since it is uniquely differentiated by both its performance profile and its convenience. KuTai is the only muscle relaxant that can be stored at room temperature. We feel confident that KuTai will continue to gain market share."
Second Quarter 2010 Results -- Sales increased 120% to $2,137,471 for the three months ended November 30, 2009, from $971,173 for the three months that ended November 30, 2008. The increase in sales was due largely to the continuing growth in sales of KuTai (cisatracurium besylate). Increased marketing efforts and adoption by physicians are driving KuTai sales growth. -- Gross margin increased 182% to $1,720,308 (80% of sales) for the three months that ended November 30, 2009, from $610,752 (63% of sales) for the three months that ended November 30, 2008. The improvement in gross margin was attributable to operating leverage; as volume increased, the unit cost of manufacturing KuTai has decreased. The improvement in gross margin was also attributable to an increase in the price of KuTai, which is distributed through a GSP licensed distributor while Sinobiopharma controls marketing, delivery terms and pricing. -- The operating expenses for the three months ended November 30, 2009 were $596,154, representing a 63% decrease as compared to $1,594,819 for the three months that ended November 30, 2008. The drop was primarily attributable to the decrease in stock-based compensation expenses, and to a lesser degree to a decline in expenses from reverse takeover activities in the three months that ended November 30, 2008. -- Research and development expenses increased $189,396 from $33,015 for the three months ended November 30, 2008 to $222,411 for the three months that ended November 30, 2009. The increase was mainly due to the technology consulting expenses related to the new drug YiTai (perindopril), for which Sinobiopharma scaled up for production in November 2009, and expenditures related to the research and development of other new drugs during the three-month period that ended November 30, 2009. -- Other expenses decreased $10,568 from $61,172 for the three months that ended November 30, 2008 to $50,604 for the three months that ended November 30, 2009. This decrease was due to a lowered balance of the shareholder loan, which resulted in lower imputed interest expenses.
Business Outlook
Dr. Huang expects strong results to continue with the launch of Sinobiopharma's newest drug YiTai (perindopril), which has obtained all approvals for production. The Company believes that YiTai will be launched as a first-to-market drug and therefore will enjoy marketing exclusivity and a price premium. There has been strong demand for YiTai to date, and strong sales will help to diversify the revenue stream from Sinobiopharma's product portfolio.
About Sinobiopharma
Sinobiopharma Inc. is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, one of the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.
FORWARD LOOKING STATEMENTS
This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward- looking statement, except as required under applicable law.
tuna
Chinese SNBP .26 check these awesome stats from latest earnings report:
Announces Second Quarter 2010 Financial Results
Revenue Increases to Approximately $2.1 Million; Net Income Increases to Approximately $1.1 Million
Press Release Source: Sinobiopharma, Inc. On Tuesday January 19, 2010, 8:30 am EST
NANTONG CITY, China, Jan. 19 /PRNewswire-Asia-FirstCall/ -- Sinobiopharma, Inc. (OTC Bulletin Board: SNBP, "Sinobiopharma" or the "Company"), a fully integrated and highly innovative biopharmaceutical company engaged in the research and development, manufacture and marketing of pharmaceutical products in China, today announced financial results for the second quarter ended November 30, 2009.
Second Quarter 2010 Highlights -- Total revenue increased by 120% year over year to approximately $2.1 million. -- Gross margin increased 182% year over year to approximately $1.7 million, or 80% of sales. -- Net income increased $2.1 million from a net loss of approximately $1.0 million in the second quarter of 2009 to net income of approximately $1.1 million in the second quarter of 2010. -- The Company scaled up of production and marketing to launch Sinobiopharma's new drug YiTai (perindopril).
"We achieved excellent revenue and net income growth in the second quarter," said Dr. Lequn Huang, Sinobiopharma's Chairman and CEO stated. "The strong growth is largely due to our increased marketing efforts and strong demand for our main product KuTai (cisatracurium besylate). KuTai is replacing older-generation muscle relaxants since it is uniquely differentiated by both its performance profile and its convenience. KuTai is the only muscle relaxant that can be stored at room temperature. We feel confident that KuTai will continue to gain market share."
Second Quarter 2010 Results -- Sales increased 120% to $2,137,471 for the three months ended November 30, 2009, from $971,173 for the three months that ended November 30, 2008. The increase in sales was due largely to the continuing growth in sales of KuTai (cisatracurium besylate). Increased marketing efforts and adoption by physicians are driving KuTai sales growth. -- Gross margin increased 182% to $1,720,308 (80% of sales) for the three months that ended November 30, 2009, from $610,752 (63% of sales) for the three months that ended November 30, 2008. The improvement in gross margin was attributable to operating leverage; as volume increased, the unit cost of manufacturing KuTai has decreased. The improvement in gross margin was also attributable to an increase in the price of KuTai, which is distributed through a GSP licensed distributor while Sinobiopharma controls marketing, delivery terms and pricing. -- The operating expenses for the three months ended November 30, 2009 were $596,154, representing a 63% decrease as compared to $1,594,819 for the three months that ended November 30, 2008. The drop was primarily attributable to the decrease in stock-based compensation expenses, and to a lesser degree to a decline in expenses from reverse takeover activities in the three months that ended November 30, 2008. -- Research and development expenses increased $189,396 from $33,015 for the three months ended November 30, 2008 to $222,411 for the three months that ended November 30, 2009. The increase was mainly due to the technology consulting expenses related to the new drug YiTai (perindopril), for which Sinobiopharma scaled up for production in November 2009, and expenditures related to the research and development of other new drugs during the three-month period that ended November 30, 2009. -- Other expenses decreased $10,568 from $61,172 for the three months that ended November 30, 2008 to $50,604 for the three months that ended November 30, 2009. This decrease was due to a lowered balance of the shareholder loan, which resulted in lower imputed interest expenses.
Business Outlook
Dr. Huang expects strong results to continue with the launch of Sinobiopharma's newest drug YiTai (perindopril), which has obtained all approvals for production. The Company believes that YiTai will be launched as a first-to-market drug and therefore will enjoy marketing exclusivity and a price premium. There has been strong demand for YiTai to date, and strong sales will help to diversify the revenue stream from Sinobiopharma's product portfolio.
About Sinobiopharma
Sinobiopharma Inc. is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, one of the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.
FORWARD LOOKING STATEMENTS
This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward- looking statement, except as required under applicable law.
Added this one to both my and wife's IRA's the past week! tuna
Sounds good Wiseman!! tuna
Yeah million! LPIH 2.25 +.20 also presents at 10:30am EDT at the NASDAQ site in NYC tomorrow!! Having a big day...tuna
SCLN 3.83 +.08 new HOD...looking good today!
WOW!!! What a mover EWPI today Wiseman...congrats to all in it!!
Biotech SCLN 3.80 +.05 HOD...
Sweet one million!! BLGW .99 +.025 now at the previous all-time high price broken this morning on a pop to $1.01 early today...looking for late strength to push it back up there into the close as it's trading with strong volume today! GL...tuna
Gapper CREG 5.25 -.48 like Thur. earnings on this new NASDAQ Chinese company:
China Recycling Energy Corporation Announced Record Full Year 2009 Results and the Fiscal Year 2010 Guidance
Revenues increase 130% to $44.2 million in 2009, up from $19.2 Million in 2008
Net Income increased by approximately $11.9 million from 2008
2010 Guidance: Revenue in the range of $68-72 million, with $18-20 million net income, exclusive of non-cash expenses
Print..Press Release Source: China Recycling Energy Corp. On Thursday March 18, 2010, 8:00 am EDT
XI'AN, China, March 18 /PRNewswire-Asia-FirstCall/ -- China Recycling Energy Corp. (OTC Bulletin Board: CREG; "CREG" or "the Company"), a leading industrial waste-to-energy solution provider in China, on March 16, 2010 announced its full year 2009 financial results and its fiscal year 2010 business guidance.
09 Results Highlight: -- Revenues grew by 130% to $44.2 million for the year ended December 31, 2009 from $19.2 million for the year ended December 31, 2008. -- Income from operations grew by 229% to $13.5 million for the year ended December 31, 2009 from $4.1 million for the year ended December 31, 2008. -- Net income grew to $9.7 million for the year ended December 31, 2009 from approximately a net loss of $2.2 million for the year ended December 31, 2008. -- Fully diluted EPS of $0.21 for the year ended December 31, 2009 versus a loss of $(0.07) for the year ended December 31, 2008. -- Non-GAAP net income grew by 348.5% to $ 13.59 million from the year ended December 2009 from $3.9 million for year ended December 2008. Non-GAAP EPS was $ 0.29 for the year ended December 2009, compared to $0.08 for the year ended December 31 2008
Suggest reading the entire report...impressive imho...tuna
CREG 5.20 -.53 check earnings from Thurs:
China Recycling Energy Corporation Announced Record Full Year 2009 Results and the Fiscal Year 2010 Guidance
Revenues increase 130% to $44.2 million in 2009, up from $19.2 Million in 2008
Net Income increased by approximately $11.9 million from 2008
2010 Guidance: Revenue in the range of $68-72 million, with $18-20 million net income, exclusive of non-cash expenses
Press Release Source: China Recycling Energy Corp. On Thursday March 18, 2010, 8:00 am EDT
XI'AN, China, March 18 /PRNewswire-Asia-FirstCall/ -- China Recycling Energy Corp. (OTC Bulletin Board: CREG; "CREG" or "the Company"), a leading industrial waste-to-energy solution provider in China, on March 16, 2010 announced its full year 2009 financial results and its fiscal year 2010 business guidance.
09 Results Highlight: -- Revenues grew by 130% to $44.2 million for the year ended December 31, 2009 from $19.2 million for the year ended December 31, 2008. -- Income from operations grew by 229% to $13.5 million for the year ended December 31, 2009 from $4.1 million for the year ended December 31, 2008. -- Net income grew to $9.7 million for the year ended December 31, 2009 from approximately a net loss of $2.2 million for the year ended December 31, 2008. -- Fully diluted EPS of $0.21 for the year ended December 31, 2009 versus a loss of $(0.07) for the year ended December 31, 2008. -- Non-GAAP net income grew by 348.5% to $ 13.59 million from the year ended December 2009 from $3.9 million for year ended December 2008. Non-GAAP EPS was $ 0.29 for the year ended December 2009, compared to $0.08 for the year ended December 31 2008
This is just the highlights...suggest reading the entire report! Love the growth in revs and net income on this newly NASDAQ company!! tuna
BLGW .98 x .99 volume still coming in nicely...crack and hold a buck today!!
BLGW .975 x .98 tight spread big volume hit new all-time high of $1.01 early this morning...watch for run up into the close possibly imho...tuna
Chinese LPIH 2.15 +.10 presents at the NASDAQ Market site in NYC tomorrow at 10:30am EDT:
Longwei Petroleum Investment Holding to Present at the March 2010 RedChip New York Equities Growth Conference
Press Release Source: Longwei Petroleum Investment Holding Limited On Wednesday March 10, 2010, 9:17 am EST
TAIYUAN CITY, China, March 10 /PRNewswire-Asia-FirstCall/ -- Longwei Petroleum Investment Holding Ltd. (OTC Bulletin Board: LPIH; "Longwei" or the "Company"), a company who transports, markets and sells finished petroleum products in the People's Republic of China, today announced that Chief Financial Officer James Crane is scheduled to present at the 2010 RedChip New York Equities Growth Conference being held March 23-24 in New York City. The Company's presentation is scheduled for 10:30 a.m. EDT on Tuesday, March 23, 2010 at the NASDAQ Market Site (4 Times Square).
Mr. Crane will discuss Longwei's financial performance, guidance for the full fiscal year 2010 and fiscal 2011, and provide an operational update on the new oil depot at Gujiao City.
Company presentations will be webcast live via http://www.RedChip.com and archived for 90 days.
RedChip investor conferences are a nationally known forum for emerging growth companies to present their stories before hundreds of investment bankers, fund managers, institutional and accredited investors, and research analysts. For this event, RedChip brings together leading investors, market leaders, and high-growth companies for two full days of dynamic presentations and Q&A sessions by CEOs and executive teams.
For additional information or to schedule a one-on-one meeting with the Company at this event, please contact Jon Cunningham at 407-644-4256, Ext. 107, or email conference@redchip.com.
About Longwei Petroleum Investment Holding Limited
Longwei Petroleum Investment Holding, Limited (http://www.longweipetroleum.com) is an energy company that, through its subsidiaries, engages in oil and gas operations in the People's Republic of China ("PRC"). Oil and gas operations consist of transporting, marketing and selling finished petroleum products. The Company's headquarters and primary facilities are located in Taiyuan City, Shanxi Province ("Shanxi"). The Company's second facility is located in Gujiao, Shanxi. The Company purchases diesel, gasoline, fuel oil and kerosene (the "Products") from various petroleum refineries in the PRC. The Company is 1 of 3 licensed intermediaries in Taiyuan City and the sole licensed intermediary in Gujiao that operates its own large scale storage tanks. The Company has the necessary licenses to operate and sell Products not only in Shanxi but throughout the entire PRC. The Company's storage tanks have the largest storage capacity of any non- government operated entity in Shanxi. The Company seeks to earn profits by selling its Products at competitive prices to large-scale gas stations, coal plants, other power-supply customers and small, independent gas stations. The Company also earns revenue by acting as a purchasing agent for other intermediaries in Shanxi and through the sale of diesel and gasoline at gas stations located at each of the Company's facilities. The sales price and the cost basis of the Company's products are largely dependent on the price of crude oil. The price of crude oil is subject to fluctuation due to a variety of factors, all of which are beyond the Company's control.
About RedChip Companies, Inc.
RedChip Companies is an international, small-cap research and financial public relations firm headquartered in Orlando, Florida; with affiliate offices in Beijing, China; Paris, France; and Seoul, Korea. Since 1993, RedChip has been a source for small-cap research and investor awareness services for emerging growth companies, delivering concrete, measurable results for its clients through its extensive national and international network of small-cap institutional and retail investors. To learn more about RedChip's products and services please visit: http://www.redchip.com/visibility/productsandservices.asp .
"Discovering Tomorrow's Blue Chips Today"(TM) For more information, please contact: Investor Relations: Dave Gentry RedChip Companies, Inc. Tel: +1-407-644-4256 x104 Jon Cunningham RedChip Companies, Inc. Tel: +1-407-644-4256 x107 Email: info@redchip.com Web: http://www.RedChip.com James Crane, Chief Financial Officer Longwei Petroleum Investment Holding Ltd. U.S.: +1-617-699-6325 P.R.C.: +86-186-0125-0891 Web: http://www.longweipetroleum.com
tuna
ALERT: LPIH 2.15 +.10 presents in NYC tomorrow at 10:30am EST:
Longwei Petroleum Investment Holding to Present at the March 2010 RedChip New York Equities Growth Conference
Press Release Source: Longwei Petroleum Investment Holding Limited On Wednesday March 10, 2010, 9:17 am EST
TAIYUAN CITY, China, March 10 /PRNewswire-Asia-FirstCall/ -- Longwei Petroleum Investment Holding Ltd. (OTC Bulletin Board: LPIH; "Longwei" or the "Company"), a company who transports, markets and sells finished petroleum products in the People's Republic of China, today announced that Chief Financial Officer James Crane is scheduled to present at the 2010 RedChip New York Equities Growth Conference being held March 23-24 in New York City. The Company's presentation is scheduled for 10:30 a.m. EDT on Tuesday, March 23, 2010 at the NASDAQ Market Site (4 Times Square).
Mr. Crane will discuss Longwei's financial performance, guidance for the full fiscal year 2010 and fiscal 2011, and provide an operational update on the new oil depot at Gujiao City.
Company presentations will be webcast live via http://www.RedChip.com and archived for 90 days.
RedChip investor conferences are a nationally known forum for emerging growth companies to present their stories before hundreds of investment bankers, fund managers, institutional and accredited investors, and research analysts. For this event, RedChip brings together leading investors, market leaders, and high-growth companies for two full days of dynamic presentations and Q&A sessions by CEOs and executive teams.
For additional information or to schedule a one-on-one meeting with the Company at this event, please contact Jon Cunningham at 407-644-4256, Ext. 107, or email conference@redchip.com.
About Longwei Petroleum Investment Holding Limited
Longwei Petroleum Investment Holding, Limited (http://www.longweipetroleum.com) is an energy company that, through its subsidiaries, engages in oil and gas operations in the People's Republic of China ("PRC"). Oil and gas operations consist of transporting, marketing and selling finished petroleum products. The Company's headquarters and primary facilities are located in Taiyuan City, Shanxi Province ("Shanxi"). The Company's second facility is located in Gujiao, Shanxi. The Company purchases diesel, gasoline, fuel oil and kerosene (the "Products") from various petroleum refineries in the PRC. The Company is 1 of 3 licensed intermediaries in Taiyuan City and the sole licensed intermediary in Gujiao that operates its own large scale storage tanks. The Company has the necessary licenses to operate and sell Products not only in Shanxi but throughout the entire PRC. The Company's storage tanks have the largest storage capacity of any non- government operated entity in Shanxi. The Company seeks to earn profits by selling its Products at competitive prices to large-scale gas stations, coal plants, other power-supply customers and small, independent gas stations. The Company also earns revenue by acting as a purchasing agent for other intermediaries in Shanxi and through the sale of diesel and gasoline at gas stations located at each of the Company's facilities. The sales price and the cost basis of the Company's products are largely dependent on the price of crude oil. The price of crude oil is subject to fluctuation due to a variety of factors, all of which are beyond the Company's control.
About RedChip Companies, Inc.
RedChip Companies is an international, small-cap research and financial public relations firm headquartered in Orlando, Florida; with affiliate offices in Beijing, China; Paris, France; and Seoul, Korea. Since 1993, RedChip has been a source for small-cap research and investor awareness services for emerging growth companies, delivering concrete, measurable results for its clients through its extensive national and international network of small-cap institutional and retail investors. To learn more about RedChip's products and services please visit: http://www.redchip.com/visibility/productsandservices.asp .
"Discovering Tomorrow's Blue Chips Today"(TM) For more information, please contact: Investor Relations: Dave Gentry RedChip Companies, Inc. Tel: +1-407-644-4256 x104 Jon Cunningham RedChip Companies, Inc. Tel: +1-407-644-4256 x107 Email: info@redchip.com Web: http://www.RedChip.com James Crane, Chief Financial Officer Longwei Petroleum Investment Holding Ltd. U.S.: +1-617-699-6325 P.R.C.: +86-186-0125-0891 Web: http://www.longweipetroleum.com
tuna
Chinese energy LPIH 2.15 x 2.16 moving up again w/2.18 HOD so far!
Ask getting bought on BLGW at .98 here...nice volume and looking higher imho...tuna
APT 3.34 -.05 continues to improve ask 3.37 now!
BLGW .98 +.015 on strong volume for it! Watch for a close above a buck today with momo coming in if it does imho...tuna
APT 3.30 -.09 bouncing off 3.15 LOD...had strong earnings a couple of weeks back!
LPIH 2.18 +.13 strong start...due for a big pop after getting hit hard...tuna
Chinese energy LPIH 2.15 +.10 cranking!!!
Looks like BLGW hit 1.01 a new all-time high briefly now .97 x .975 +.005 here on good volume! Attack a buck again and close over a dollar would be great!
Chinese energy co. LPIH 2.11 +.06 now!